NewLimit — Startup Profile

Reprogramming cells to treat age-related disease

HQ: South San Francisco, CA | Founded: 2021 | Employees: Not publicly disclosed | Stage: Clinical-stage biotech | Website: https://newlimit.com

About

NewLimit researches changing how cells use their genetic instructions approaches intended to restore youthful cellular function and ultimately address diseases associated with aging.

The Take

NewLimit combines frontier cell biology with unusually large startup financing and a highly ambitious thesis. The investment case depends on translating cellular reprogramming into safe, repeatable therdeveloper toolses.

proof in clinical studies, delivery, and long timelines are the dominant risks.

Key Metrics

• Founded: 2021
• Founders: Brian Armstrong; Blake Byers; Jacob Kimmel
• Latest reported round: $435M Series C
• Funding rounds cited: 2

Funding Rounds

• Round: $435M (2026-06) — Founders Fund
• Round: $130M reported (2025) — Not fully disclosed

Key People

• Brian Armstrong
• Blake Byers
• Jacob Kimmel

Key Competitors

• Incumbent platforms —
• Specialist startups —

Timeline Highlights

• 2025: Series B
• 2026-06: Growth financing
• 2021: Founded

Recent News

• NewLimit raises $435M for longevity research (2026-06-02)

Similar Startups

• Aether Biomachines — Designing industrial proteins with computers and biology.
• Enveda Biosciences — Finding medicines in the chemistry of nature.
• Chai Discovery — The computer-aided design suite for molecules
• Cellares — Automated manufacturing for cell therapies
• Converge Bio — Generative AI for drug discovery and development

Browse: Home | Blog | About | All Startups A-Z | View full profile on StartupWiki